Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to -$11.9 million.

  • Treace Medical Concepts' Free Cash Flow rose 1906.83% to -$11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.3 million, marking a year-over-year increase of 3901.15%. This contributed to the annual value of -$48.8 million for FY2024, which is 592.4% down from last year.
  • Latest data reveals that Treace Medical Concepts reported Free Cash Flow of -$11.9 million as of Q3 2025, which was up 1906.83% from -$7.8 million recorded in Q2 2025.
  • Over the past 5 years, Treace Medical Concepts' Free Cash Flow peaked at $655000.0 during Q1 2025, and registered a low of -$18.7 million during Q1 2023.
  • Moreover, its 5-year median value for Free Cash Flow was -$10.2 million (2021), whereas its average is -$9.4 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 125856.7% in 2022, then surged by 10587.55% in 2025.
  • Quarter analysis of 5 years shows Treace Medical Concepts' Free Cash Flow stood at -$4.7 million in 2021, then tumbled by 65.09% to -$7.7 million in 2022, then soared by 77.66% to -$1.7 million in 2023, then crashed by 324.3% to -$7.3 million in 2024, then plummeted by 63.45% to -$11.9 million in 2025.
  • Its last three reported values are -$11.9 million in Q3 2025, -$7.8 million for Q2 2025, and $655000.0 during Q1 2025.